Sign Out
In clinical studies, administration of ezetimibe, 50 mg/day to healthy subjects for up to 14 days, 40 mg/day to patients with primary hypercholesterolemia for up to 56 days, and 40 mg/day to patients with homozygous sitosterolemia for 26 weeks, was generally well tolerated.
A few cases of overdosage with ezetimibe have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. In the event of an overdose, symptomatic and supportive measures should be employed.
